0.669
0.06 (10.49%)
Penutupan Terdahulu | 0.605 |
Buka | 0.658 |
Jumlah Dagangan | 1,750,520 |
Purata Dagangan (3B) | 1,455,286 |
Modal Pasaran | 47,565,148 |
Harga / Jualan (P/S) | 78.42 |
Harga / Buku (P/B) | 0.730 |
Julat 52 Minggu | |
Tarikh Pendapatan | 14 Aug 2025 |
Margin Operasi (TTM) | -9,653.85% |
EPS Cair (TTM) | -0.340 |
Pertumbuhan Hasil Suku Tahunan (YOY) | -12.20% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 24.34% |
Nisbah Semasa (MRQ) | 4.93 |
Aliran Tunai Operasi (OCF TTM) | -49.55 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -27.61 M |
Pulangan Atas Aset (ROA TTM) | -31.37% |
Pulangan Atas Ekuiti (ROE TTM) | -36.31% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Menurun |
Biotechnology (Global) | Bercampur | Menurun | |
Stok | Ovid Therapeutics Inc. | Menurun | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | -0.5 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -2.0 |
Purata Bergerak Teknikal | 2.5 |
Osilator Teknikal | 2.0 |
Purata | 0.50 |
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Value |
% Dimiliki oleh Orang Dalam | 16.31% |
% Dimiliki oleh Institusi | 55.97% |
Julat 52 Minggu | ||
Median | 1.50 (124.25%) | |
Jumlah | 1 Beli |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
HC Wainwright & Co. | 27 May 2025 | 1.50 (124.25%) | Beli | 0.291 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
23 Jul 2025 | Pengumuman | Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference |
25 Jun 2025 | Pengumuman | Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties |
05 Jun 2025 | Pengumuman | Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 |
13 May 2025 | Pengumuman | Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |